{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:03:37Z","timestamp":1790661817337,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"S1","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>Chimeric antigen receptor modified T (CAR\u2010T) cell therapy against the CD19 antigen has revolutionized the therapeutic landscape for patients with relapsed, refractory B cell non\u2010Hodgkin lymphoma (NHL). Currently, there are two FDA approved products (axicabtagene ciloleucel and tisagenlecleucel) for B cell NHL, with several other constructs under clinical investigation. This review will focus on the clinical outcomes, toxicity profile, and differences among candidate CD19 CAR\u2010T cell products for major subtypes of B cell NHL including diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma. Lastly, we will describe novel CAR\u2010T constructs currently under exploration in B cell NHL.<\/jats:p>","DOI":"10.1002\/ajh.25403","type":"journal-article","created":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T06:59:09Z","timestamp":1547708349000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Chimeric antigen receptor modified T cell therapy in B cell non\u2010Hodgkin lymphomas"],"prefix":"10.1002","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6971-5037","authenticated-orcid":false,"given":"Adam","family":"Levin","sequence":"first","affiliation":[{"name":"Division of Hematology &amp; Oncology Medical College of Wisconsin Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4336-1071","authenticated-orcid":false,"given":"Nirav N.","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Hematology &amp; Oncology Medical College of Wisconsin Milwaukee Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1706169"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-02-629063"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1387905"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2018.07.011"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.5472"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.567"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14136"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-041871"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-577189"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_8_14_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B\u2010cell lymphoma with primary treatment failure: ultra\u2010high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa LJ","year":"2016","journal-title":"Am J Hematol"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059636"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_8_20_1","first-page":"581","article-title":"High durable CR rates in relapsed\/refractory (R\/R) aggressive B\u2010NHL treated with the CD19\u2010directed CAR T cell product JCAR017 (TRANSCEND NHL 001): defined composition allows for dose\u2010finding and definition of pivotal cohort","volume":"130","author":"Abramson JS","year":"2017","journal-title":"Blood"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaf8621"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S145039"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201607485"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1530"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24937"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-624288"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5904"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-03-791392"},{"key":"e_1_2_8_31_1","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1182\/blood.V128.22.5393.5393","article-title":"Anti\u2010CD19 chimeric antigen receptor T cells improve responses to chemotherapy\u2010refractory mantle cell lymphoma: a case report","volume":"128","author":"Chen W","year":"2016","journal-title":"Blood"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110194"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0212-6"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110142"},{"key":"e_1_2_8_36_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1182\/blood-2018-99-117737","article-title":"A phase I first\u2010in\u2010human clinical trial of CD19\u2010targeted 19\u201028z\/4\u20101BBL \u201cArmored\u201d CAR T cells in patients with relapsed or refractory NHL and CLL including Richter's transformation","volume":"132","author":"Park JH","year":"2018","journal-title":"Blood"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150291"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092"},{"key":"e_1_2_8_40_1","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of phase 1 results from Zuma\u20106: axicabtagene ciloleucel (Axi\u2010Cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma","volume":"132","author":"Jacobson CA","year":"2018","journal-title":"Blood"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-119502"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25403","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25403","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T04:34:04Z","timestamp":1720931644000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":40,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1002\/ajh.25403"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25403","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"2018-11-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}